Search and analyze individual stocks with comprehensive metrics
Gufic Biosciences Limited
Fundamental Score
Gufic Biosciences Limited Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of GUFICBIO across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (18.13%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Consistent Growth Track Record (16.69% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Excellent EPS Growth (19.07% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (25.26% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Balanced Promoter Holding (72.51%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
6 factors identified
Premium Valuation Risk (P/E: 60.32x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Profit Decline Concern (-42.14%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Negative Free Cash Flow (₹-184.00 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Limited Institutional Interest (FII+DII: 3.70%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Gufic Biosciences Limited
About GUFICBIO
Company Details
Market Information
Performance
GUFICBIO Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of GUFICBIO?
GUFICBIO is currently trading at ₹367.90 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of GUFICBIO shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of GUFICBIO and what does it mean?
GUFICBIO has a P/E ratio of 60.32x compared to the industry average of 33.97x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹60 for every ₹1 of annual earnings. This is higher than the industry average, suggesting either growth premium or potential overvaluation.
How is GUFICBIO performing according to Bull Run's analysis?
GUFICBIO has a Bull Run fundamental score of 43.9/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 12.33%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does GUFICBIO belong to?
GUFICBIO operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Gufic Biosciences Limited. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for GUFICBIO?
GUFICBIO has an ROE of 12.33%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Gufic Biosciences Limited generates profits from shareholders' equity. An ROE of 12% means the company generates ₹12 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is GUFICBIO's debt-to-equity ratio and what does it indicate?
GUFICBIO has a debt-to-equity ratio of 0.56, which indicates moderate leverage that should be monitored. This means the company has ₹56 of debt for every ₹100 of equity. Higher leverage can amplify returns during good times but increases bankruptcy risk during downturns.
What is GUFICBIO's dividend yield and is it a good dividend stock?
GUFICBIO offers a dividend yield of 0.03%, which means you receive ₹0.03 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has GUFICBIO grown over the past 5 years?
GUFICBIO has achieved 5-year growth rates of: Sales Growth 16.69%, Profit Growth 25.26%, and EPS Growth 19.07%. This consistent double-digit growth indicates a strong business model and competitive positioning. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in GUFICBIO and why does it matter?
Promoters hold 72.51% of GUFICBIO shares, with 0.00% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.
How does GUFICBIO compare with its industry peers?
GUFICBIO trades at P/E 60.32x vs industry average 33.97x, with ROE of 12.33% and ROCE of 13.04%. The stock trades at a premium to industry average, which may be justified by superior fundamentals. Peer comparison helps identify whether GUFICBIO is outperforming its competitive set in profitability, growth, and valuation metrics.
What is GUFICBIO's market capitalization and what category does it fall into?
GUFICBIO has a market capitalization of ₹3688 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for GUFICBIO?
Key ratios for GUFICBIO: ROE 12.33% (Good), ROCE 13.04%, P/E 60.32x, Debt-to-Equity 0.56, Interest Coverage 3.98x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is GUFICBIO stock and what is its beta?
GUFICBIO has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for GUFICBIO?
GUFICBIO has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹367.90, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in GUFICBIO?
Key risks for GUFICBIO include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.56), and operational challenges. The stock has a Fundamental Score of 43.9/100, indicating higher risk requiring thorough due diligence. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is GUFICBIO's operating profit margin and how has it trended?
GUFICBIO has a 5-year average Operating Profit Margin (OPM) of 18.13%, which is good and shows decent operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. This strong margin indicates competitive advantages and operational leverage. Compare with industry peers to understand relative performance.
How is GUFICBIO's quarterly performance in terms of sales and profit growth?
GUFICBIO's recent quarterly performance shows YoY Sales Growth of 11.88% and YoY Profit Growth of -42.14%. This shows decent growth momentum in the business. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in GUFICBIO?
GUFICBIO has FII holding of 0.32% and DII holding of 3.38%, totaling 3.70% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.